Approval of new antidepressant likely to reopen debate on attack method

Cymbalta, a new antidepressant drug expected to get FDA approval this summer, addresses the ailment by attacking two of the brain's chemicals, including norepinephrine, believed by some scientists to be linked to depression. The launch of Eli Lilly's new drug is likely to ignite new debate over whether drugs that seek to attack two chemicals at once are better than those that concentrate on a single source of depression, such as Lilly's own Prozac, a selective serotonin reuptake inhibitor.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX